U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06964230) titled 'A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects' on April 14.
Brief Summary: This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's. The aims of the trial are to affirm potential therapeutic efficacy and safety observed in earlier clinical trials and assess the potential to modify the course of disease. The drug will be compared to placebo and administered orally to patients once a day for 78 weeks.
Study Start Date: Oct. 26, 2026
Study Type: INTERVENTIONAL
Condition:
Alzheimer's Disease
Intervention:
DRUG: T...